Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stomach Neoplasms 12Neoplasms 7Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Sarcoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Advanced Solid Tumor 2Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1NSCLC 1Metastatic Castration Resistant Prostate Cancer 1Malignant Neoplasms of Digestive Organs 1Fallopian Tube Neoplasms 1Cytochrome P450 Interaction 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Advanced Primary Liver Cancer 1Advanced Cancer 1

Interventions

enzalutamide 8Abiraterone Acetate 4rucaparib 2Prednisone 2Docetaxel 2sabizabulin 1fluzoparib 1apatinib 1abiraterone 1Pluvicto 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Castration Resistant Prostate Cancer × apatinib × Clear all
NCT04869488 2025-01-24

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
93 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡